Research programme: shared oncoviral antigens targeting TCR-T cell therapies - Anocca
Alternative Names: HPV-16- E7 targeting TCR-T cell therapies - Anocca; HPV-16-E6 targeting TCR-T cell therapies - AnoccaLatest Information Update: 11 Mar 2024
At a glance
- Originator Anocca
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 28 Jan 2024 Early research in Cancer in Sweden (Parenteral) (Anocca Pipeline, January 2024)